Bevacizumab Biosimilars

November 2, 2022

Dear OMIC Insureds:

An increasing number of ophthalmologists treating retinal conditions with intravitreal anti-VEGF agents are being asked by health systems and hospitals to utilize bevacizumab biosimilar drugs. Both the AAO (2022) and CMS (2021) have issued statements recommending against the use of off-label bevacizumab biosimilars to treat ocular conditions due to insufficient data regarding long-term efficacy and safety profiles. OMIC supports these statements and strongly recommends against the use of bevacizumab biosimilar drugs for intravitreal injection, as well as off-label use of all biosimilars for the treatment of ROP until further clinical data becomes available.

If you have questions about this topic or would like to have a confidential risk management consultation, please email riskmanagement@omic.com or 1-800-562-6642, enter 4 for OMIC Risk Management.

Sincerely,

Michael C. Tigani, MD
Chair, OMIC Risk Management Committee

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Largest insurer in the U.S.

OMIC is the largest insurer of ophthalmologists in the United States and we've been the only physician-owned carrier to continuously offer coverage in all states since 1987. Our fully portable policy can be taken with you wherever you practice. Should you move to a new state or territory, you're covered without the cost or headache of applying for new coverage.

Risk Management

Bevacizumab Biosimilars